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Reduced glomerular thromboxane receptor sites and vasoconstrictor
responses in diabetic rats. Glomerular thromboxane production and
urinary thromboxane excretion are increased in early diabetes, but in
spite of this renal blood flow and glomerular filtration rate are signifi-
cantly higher than in control animals. To study the possibility of a
defect in thromboxane actions in the kidney, we have measured
glomerular thromboxane receptors and the renal hemodynamic re-
sponse to the administration of a stable thromboxane analog in diabetic
rats. Glomerular thromboxane receptors were studied in hyperglycemic
diabetic rats 7 to 10 days after injection of streptozotocin (65 mg/kg,
iv.) and in normal controls. Scatchard analysis of equilibrium binding
using the thromboxane antagonist, [3H]-SQ29548, demonstrated one
class of high affinity thromboxane receptor sites in control (Kd = 19.9
2.6 nM, N = 16) and diabetic rats (Kd = 19.8 2.1 nsi, N 8, P
NS). The number of thromboxane receptors was reduced by 44% in
diabetic rats (control, 374 20 vs. diabetic, 210 21 fmol/mg, P <
0.01). Thromboxane binding in diabetic rats was not restored to normal
levels by thromboxane synthetase inhibition with 0KY046. Diabetic
rats had higher renal blood flow (diabetic, 7.03 0.18 vs. control, 6.33
0.13 mi/mm, P < 0.05) and glomerular filtration rate (2.42 0.10 vs.
1.96 0.07 mI/mm, P < 0.05). Infusion of the stable thromboxane
agonist, tJ466l9 (0.1 jg/kg/min), reduced renal blood flow and glomer-
ular filtration rate in all animals, but the constrictor responses were
blunted by 50% in hyperglycemic diabetic rats compared with normal
controls or euglycemic diabetic rats (P < 0.05). Control of blood
glucose with insulin normalized the number of glomerular thromboxane
receptor sites, reversed hyperfiltration and restored glomerular re-
sponses to thromboxane agonist. The abnormalities of glomerular
thromboxane receptors are similar to changes in angiotensin II recep-
tors, and suggest a generalized defect in vasoconstrictor receptors in
the diabetic kidney.
Insulin dependent diabetes mellitus causes predictable
changes in renal function in humans and laboratory animals.
Shortly after the onset of diabetes there is an elevation in
glomerular filtration rate (GFR) and blood flow (RBF) which
has been postulated to contribute to later glomerular pathology
and progressive renal failure [1], Multiple lines of evidence
suggest that glomerular hyperfiltration during the early phase of
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diabetes contributes to the pathogenesis of progressive renal
impairment [1—4].
The mechanisms leading to diabetic hyperfiltration are not
known. However, it is likely that abnormal hormone-receptor
interactions play a significant role. Angiotensin II receptors are
reduced in the diabetic glomerulus at the time that hyperfiltra-
tion occurs [5—7], Elevation of plasma angiotensin II levels
either by intrarenal infusion or sodium depletion corrects hy-
perfiltration [8], suggesting that the reduced receptor density
relative to the availability of endogenous angiotensin II may
play a role in the hyperfiltration.
Data from several laboratories demonstrate that diabetic
glomeruli and aortae produce larger amounts of PGE2, PG!2 and
thromboxane than normal glomeruli, and it has been postulated
that excessive amounts of vasodilator prostaglandins contribute
to the hyperfiltration [9—13]. Less attention has been given to
possible abnormalities in the relationship between glomerular
thromboxane, thromboxane receptors and renal responses to
thromboxane in diabetes. In early diabetes thromboxane excre-
tion is increased in the urine [14—17], but in spite of this renal
blood flow and glomerular filtration rate are significantly higher
than in control animals. To determine whether changes in
thromboxane action contribute to diabetic hyperfiltration, we
have measured glomerular thromboxane receptors, and the
renal hemodynamic response to the administration of a stable
analog of thromboxane in diabetic rats.
Methods
Protocols
Thromboxane receptor studies. Experiments were performed
on adult male Sprague-Dawley rats (324 10 g) fed standard rat
chow (Ralston Purina Co., Chicago, Illinois, USA) (sodium ash
content 0.42%) and given tap water to drink ad libitum. Diabe-
tes was induced by the injection of streptozotocin (65 mg/kg
i.v.) into the jugular vein of ether anesthetized rats. Normal rats
injected with vehicle alone served as controls. The induction of
diabetes was confirmed 24 hours later by semiquantitative
urinary glucose measurements (Ames dipstick). Half of the
diabetic rats were injected subcutaneously with 10 U NPH
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insulin daily (treated diabetics) and the other half were un-
treated. Quantitative blood glucose measurements were per-
formed at the time of receptor measurements 7 to 10 days after
streptozotocin injection.
The relationship between thromboxane production and gb-
merular thromboxane binding was studied in four groups of
rats: normal, diabetic (untreated), normal plus the thromboxane
synthetase inhibitor, 0KY046 and diabetic plus 0KY046.
0KY046 treatment (20 mg/kg, s.c., b.i.d.) was begun immedi-
ately after streptozotocin or vehicle injection. Five days later
six rats from each group were placed in metabolic cages, and
urine was collected for the determination of TxB2 excretion on
days six to seven as described below. At one week the binding
of [3H]-SQ29548 to isolated glomeruli (75 g) was measured at
a single concentration of ligand (20 nM).
Additional normal rats were studied to determine the effects
of thromboxane agonist infusion on glomerular thromboxane
receptors. U466l9 (1.75 p.g/kg/min) was infused for 30 minutes
into conscious rats via catheters (PE1O) previously placed into
the aorta at the level of the renal arteries as described in detail
[18]. Rats were decapitated and the kidneys were removed for
glomerular thromboxane receptor measurements. U46619 re-
duced renal blood flow by 70% [18], but did not significantly
increase mean arterial pressure (baseline, 108 7 vs. U46619
infusion, 116 9mm Hg, P = NS).
Thromboxane receptor measurements. Rats were killed by
decapitation and glomeruli were isolated for binding studies.
The kidneys from three rats were pooled to obtain sufficient
glomeruli for each binding experiment. The kidneys were
immediately placed in chilled Tris-saline buffer (50 mrvi Tris in
0.154 M NaCl, 4°C, pH 7.5). The outer cortex was dissected,
minced to a paste-like consistency and resuspended in buffer.
Glomeruli were isolated by graded sieving using 90 m, 180 pm,
150 jtm and 75 sm stacked phosphor bronze sieves as previ-
ously described [18]. The cortical paste was pushed through the
90 m sieve onto the 180 pm sieve and washed through with 50
ml of buffer. The glomeruli retained on the 75 m sieve were
>95% pure as determined by light microscopy. The number of
gbomeruli in 20 il of glomerular suspension was counted in
duplicate. Glomerular protein content was determined using the
method of Lowry et al [19].
Aliquots of glomeruli (75 j.g of protein) were incubated in a
final volume of 0.25 ml Tris-saline at 25°C with varying amounts
of [3H]-SQ29548. The binding reaction was interrupted by a
40-fold dilution with ice-cold buffer. The samples were rapidly
filtered (Schleicher & Schuell, #30) and the trapped glomeruli
were washed with two 5 ml volumes of ice-cold buffer. After the
addition of 5 ml of Ecoscint A' (National Diagnostics Co.,
Manville, New Jersey, USA), the samples were analyzed for 3H
using a Packard Tri-Carb 4530 scintillation counter (Packard
Instrument Co., Sterling, Virginia, USA). SQ29548 (50 M)
caused maximal displacement of the ligand and defined the level
of non-specific binding. Specific binding was determined as the
difference between the amount of [3H]-SQ29548 bound in the
absence and presence of 50 M SQ29548 [18].
Equilibrium binding studies. Equilibrium binding studies
were performed at 30 minutes using eight concentrations of
[3H]-SQ29548 (0.2 to 65 nM) as previously described [181.
Binding isotherms were calculated using non-linear regression
least square curve fitting. Binding data were analyzed by the
method of Scatchard [201 to give estimates of specific binding
sites (Bmax) and apparent equilibrium affinity constants (Kd) by
using the LIGAND program of Munson and Rodbard [21]. The
number of receptors is expressed as fmol/mg protein or as
receptors per glomerulus calculated by the formula:
receptors receptor number (fmol/mg)
=
.
x
glomerulus number of glomeruh/mg
6.023 x 108 receptors
fmol
Renal hemodynamic studies
Experiments were performed on adult male Sprague-Dawley
rats (255 4 g body wt) fed standard rat chow (Ralston Purina
Co., Chicago, Illinois, USA; sodium ash content 0.42%) and
given tap water to drink ad libitum. Diabetes was induced by
the injection of streptozotocin (65 mg/kg i.v.) as in the previous
section. For hemodynamic studies the diabetic rats were di-
vided into three groups. One group of animals (N = 5) was
given NPH insulin, 2 to 3 U subcutaneously every other day to
attenuate polyuria and polydipsia, but without attempting to
normalize blood glucose (hyperglycemic diabetic rats). A sec-
ond group of diabetic rats (N = 5; short-term euglycemic
diabetic rats) was given 3.5 to 4.5 U Ultralente insulin subcu-
taneously at 3:00 PM on the day prior to the hemodynamic
study. A third group of diabetic rats (N = 6) was injected with
3.5 to 4.5 U Ultralente insulin daily from the day after strepto-
zotocin administration to the afternoon prior to study (long-
term euglycemic diabetic rats). In these two latter groups, blood
glucose was within the normal range at the time of hemody-
namic measurement. A fourth group of normal rats (N = 5)
served as non-diabetic controls. All experiments were per-
formed 7 to 10 days after the induction of diabetes.
The rats were anesthetized with mactin (100 mg/kg body wt,
i.p.) and prepared surgically for micropuncture study as previ-
ously described [7, 8, 22]. The left kidney was isolated, the
renal artery exposed, and an ultrasonic flow probe (Transonic
Systems, Inc., Ithica, New York, USA) was placed around the
artery for continuous monitoring of renal blood flow. This
method of blood flow measurement has been shown to be
independent of vessel diameter [23]. In separate experiments,
blood flow was stopped by clamping the renal artery to test the
zero point. The reading fell to 0 to 0.2 mI/mm indicating an
accurate zero point. A PE 10 polyethylene catheter was passed
from a femoral artery into the abdominal aorta until it could be
seen in the aorta 1 cm above the renal arteries. The location was
confirmed by bolus injection of a small volume of F D and C
green dye, which resulted in a flush of the kidneys. Priming and
sustaining amounts of '4C-inulin (E.I. DuPont de Nemours &
Co., Inc./NEN Products, Boston, Massachusetts, USA) were
infused i.v. via a jugular vein catheter.
Renal blood flow was measured continuously, and after timed
urine and proximal tubular fluid samples were obtained, U46619
was infused continuously into the abdominal aorta catheter at a
rate of 0.1 g/min/kg body weight. Repeat urine and proximal
tubular fluid collections were started 15 minutes later. Urine
was collected from the urinary bladder for measurement of
14C-inulin and volume and the same measurements were carried
out on proximal tubule fluid.
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Arterial blood was collected periodically throughout the
experiments from a carotid artery catheter, for measurement of
14C inulin concentration. Whole kidney glomerular filtration
rate (GFR) and single nephron glomerular filtration rate
(SNGFR) were calculated from standard equations [7, 81.
Renal hemodynamic response to thromboxane receptor
antagonist SK&F 96148
In four hyperglycemic diabetic rats treated every other day
with 2 to 3 U NPH insulin, the renal response to intra-aortic
infusion of a thromboxane receptor antagonist was measured.
The surgical preparation of the animals was the same as in the
preceding group. During a control period, RBF, GFR, and
SNGFR were measured as described above. Following this, the
thromboxane receptor antagonist, SK&F 96148, was injected
into the abdominal aorta catheter in an initial dose of 1 mg/kg,
followed by a continuous infusion of 1 mg/kg/hr. We have
previously found that this dose of SK&F 96148 given to normal
rats has no effect on MAP or GFR and only a small effect to
increase RBF by 3.5% [221. Renal blood flow, GFR, and
SNGFR measurements were repeated during the infusion of the
thromboxane receptor antagonist.
Meausrement of urinary TxB2. Two studies were performed
to measure urinary TxB2 excretion. In one study timed over-
night urine collections were obtained in normal and diabetic rats
treated intermittently with 1 to 2 U of NPH insulin. The urine
was collected into vials containing 0.3 iM meclofenamate and
frozen at —70°C until assayed. An enzyme immunoassay for
TxB2 ws used, as described previously [221 using a TxB2
antibody kindly provided by Dr. P. Pradelles [24]. In a second
study we determined the effects of the thromboxane synthetase
inhibitor, 0KY046, on urinary thromboxane excretion, In brief,
24 hour urines were collected from normal and diabetic rats
(without insulin treatment). Half of each group was treated with
0KY1J46 as described above and urines were stored at —70°C
until assay. Urine was extracted using SepPak cartridges [251
and TxB2 quantitated by radioimmunoassay as previously de-
scribed using a commercial TxB2 antibody (Advanced Magnet-
ics Co., Cambridge, Massachusetts, USA) [26]. All samples
were analyzed at the same time in order to avoid interassay
variations.
Data analysis. Data are presented as the mean standard
error. In the micropuncture experiments average data from the
control period and from the experimental period were used in
paired t-test analysis. All other data analysis was performed by
ANOVA followed by the Student-Newman-Keuls method for
multiple comparisons using the SAS program on an IBM AT
computer. Where appropriate the Wilcoxon ranks sum test was
used. The null hypothesis was rejected when the P <0.05.
Materials. Thromboxane B2 was purchased from Upjohn
Diagnostics (Kalamazoo, Michigan, USA). 5 ,6,-[3H]-[ IS-
[1 a,2f3(5Z),
zinojmethyl] -7- oxabicyclo-[2.2. 1 .ihept-2-yl]-5-heptenoic acid
([3H]-SQ29548) purchased from E.I. DuPont de Nemours &
Co., Inc. had a specific activity of 40 Ci/mmol. 9a, I a-metha-
noepoxy-PGH2 (U46619) was purchased from Cayman Chemi-
cals Company (Ann Arbor, Michigan, USA). SQ29548 was a
gift of Dr. Martin Ogletree of the Squibb Institute for Medical
Research. SK&F 96148 was provided by Smith, Kline &
0.000
Bound, fmol/mg
Fig. 1. Scatchard plots of saturation binding of [3H1-SQ29548 to
isolated gloineruli from normal (circles) and diabetic rats (squares).
There was one class of high affinity thromboxane receptor sites in
control (Kd = 15.8 nM) and diabetic rats (Kd 15.1). In this experiment
the number of thromboxane receptors was reduced by 55% in diabetic
rats (control, 464 vs. diabetic, 207 fmol/mg). Points are means of
triplicate measurements in representative experiments.
French Research Laboratories (Swedeland, Pennsylvania,
USA) and 0KY046, (E)-3-[4-(imidazolylmethyl)phenyl]-2-pro-
panoic acid, was provided by Ono Pharmaceutical Company,
Osaka, Japan. All chemicals were purchased at the highest
grade available.
Results
Ligand binding studies
At the time of receptor measurements diabetic rats had
elevated plasma glucose concentrations (498 22 mg/dl, N
27, P < 0.001) compared with either insulin-treated diabetics
(73 12 mg/dl, N = 15) or normal controls (104 10 mg/dl, N
= 30). There was no difference in glomerular protein content in
control (70.7 6.2 ng/glomerulus, N 16) versus untreated
diabetic rats (68.5 8.2 ng/glomerulus, N = 8) consistent with
previously reported data [6]. Scatchard analysis of equilibrium
binding using the thromboxane antagonist, [3H]-SQ29548,
showed that there was one class of thromboxane receptor sites
that was of similar affinity in control (Kd = 19.9 2.6 nM, N
16) and diabetic rats (Kd = 19.8 2.1 nM, N = 8,P = NS; Fig.
1). Specific binding was saturable in normal and diabetic
glomeruli and accounted for 39 to 69% of total binding. Com-
pared with control rats, there was a 44% reduction in the
number of glomerular thromboxane receptor sites in untreated
diabetic rats (control, 374 20 vs. diabetic, 210 21 fmol/mg,
P < 0.01; Fig. 2). The reduction in binding was similar if
analyzed as fmol/mg protein or receptor sites/glomerulus (con-
trol, 16.2 2.0 vs. untreated diabetic, 8.4 0.8 million
receptors/glomerulus, P < 0.01). Treatment of hyperglycemia
with insulin (10 U NPH insulin daily) restored glomerular
thromboxane receptors to control levels (444 39 fmol/mg or
15.3 3.0 million receptors/glomerulus, P NS vs. control;
Fig. 2). In all subsequent studies glomerular thromboxane
receptors are expressed as fmoL'mg protein.
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Fig. 2. Glomerular thromboxane receptors in untreated and insulin-
treated diabetic rats. There was a 44% reduction in the number of
glomerular thromboxane receptors in hyperglycemic diabetic rats at
one week. Insulin treatment (10 U daily) reversed hyperglycemia in
diabetic rats and normalized thromboxane receptor density. Abbrevia-
tions: N = control; D = untreated diabetic; D + I = treated diabetics.
* indicates P < 0.01 vs. N and D + I groups.
Urinary thromboxane excretion in diabetic rats
Urinary TxB2 excretion was increased in diabetic rats. Using
an enzyme linked immunoassay on overnight urine collections,
normal rats excreted 133 12 ng/kg/24 hr and diabetic rats
excreted 241 21 nglkg/24 hr of TxB2, (P < 0.01). A second
independent determination of urinary thromboxane excretion
by radioimmunoassay gave overall lower values for urinary
thromboxane excretion. However, the data from radioimmuno-
assay confirmed the rise in urinary thromboxane excretion in
diabetic rats (see below).
Effects of thromboxane synthetase inhibition on glomerular
thromboxane receptors
If the reduced number of thromboxane receptors in diabetes
was due to homologous downregulation by increased throm-
boxane levels, inhibition of thromboxane production with
0KY046 would be expected to prevent the reduction in recep-
tors. As shown in Table 1, 0KY046 reduced 24-hour throm-
boxane excretion by 49% in normal rats. Untreated diabetic rats
had a doubling of urinary thromboxane excretion. The admin-
istration of 0KY046 to diabetic rats prevented the increased
excretion of thromboxane: urinary TxB2 levels in 0KY046-
treated diabetics were indistinguishable from TxB2 excretion in
normal controls. Despite maintenance of normal urinary TxB2
excretion in diabetic rats treated with 0KY046, there was a
40% reduction in specific binding of [3H1-SQ29548 compared
with normal untreated rats (P < 0.05). Thromboxane binding
was reduced in diabetic rats independent of levels of urinary
TxB2 excretion.
Effects of short-term U46619 infusion
A small number of experiments was performed to determine
the effect of U46619 on glomerular thromboxane binding sites.
U466l9 infusion into normal rats did not change the number or
affinity of glomerular thromboxane receptor sites [control; Kd,
19.9 2.6 nM; receptor number, 374 20 fmol/mg (N = 16) vs.
U46619; Kd 14.2 2.3 nM; receptor number, 396 38 fmolfmg
(N = 4); P = NS].
Table 1. Effects of 0KY046 on urinary thromboxane excretion and
glomerular 13H1-SQ29548 binding in normal and diabetic rats
Urinary TxB2 F3H]-SQ29548 binding
Group ng/kg124 hr fmollmg
Normal 60.3 13.8 185.8 19.0
(6) (15)
Normal + 0KY046 30.5 7.6a 161.7 13.5
(5) (10)
Diabetic 127.4 75b 97.2 74C
(6) (8)
Diabetic + 0KY046 82.7 4.8 111.7 14.9c
(6) (10)
Effect of glycemic control on renal hemodynamics. Table 2
shows data from normal, hyperglycemic, and diabetic rats
treated with Ultralente insulin for either 18 hours or 7 to 10 days
before study. The hyperglycemic animals had significantly
higher RBF, GFR and SNGFR than the normal controls. The
diabetic rats that received a single dose of Ultralente insulin 18
hours prior to study were euglycemic on the day of study. GFR
and SNGFR remained higher than in the normal rats, although
RBF was decreased to a value not different from the normal
rats. In diabetic rats treated with daily injections of Ultralente
insulin for 7 to 10 days, RBF, GFR, and SNGFR were all
comparable to values in the normal rats. These observations are
in agreement with those of Jensen Ct al [27].
Effects of thromboxane agonist on renal hemodynamics
The effects of intra-aortic infusion of the thromboxane ago-
nist, U46619, on renal hemodynamics are shown in Table 3 and
Figure 3. A low dose of U46619 was used (0.1 g/min/kg body
wt) which caused a 20% reduction in whole kidney GFR and
RBF, and a 25% reduction in SNGFR in normal rats. In the
hyperglycemic diabetic rats, the same dose of U46619 produced
only a 12% fall in GFR and RBF, and a 14% fall in SNGFR. The
differences between the two groups were statistically signifi-
cant. In sharp contrast in the diabetic rats treated with UI-
tralente insulin for 18 hours before study to normalize blood
glucose, the renal response to U46619 was indistinguishable
from that in normal rats, When expressed as absolute changes
(Table 3), the response to U46619 was also statistically different
in the three groups. Thus, GFR fell 0.38 0.03 ml/min in the
normal rats versus 0.26 0.04 mI/mm in the hyperglycemic
diabetics; RBF fell 1.21 0.15 mI/mm in the normals versus
0.69 0.18 ml/min in the hyperglycemic diabetics. The absolute
values of SNGFR also fell to a lesser extent in the hyperglyce-
mic diabetics, but the data did not reach statistical significance.
In the euglycemic diabetic rats, the absolute decrements in
RBF, GFR and SNGFR were all significantly greater than in the
hyperglycemic diabetic rats. As noted in Table 3 there were no
significant changes in mean arterial pressure in any of the
groups infused with U466l9.
Effect of thromboxane receptor antagonist on renal
hemodynamics
The results of measurements of RBF, GFR, and SNGFR in
hyperglycemic diabetic rats before and during intra-aortic infu-
sion of the thromboxane receptor antagonist, SK&F 96148, are
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0 P < 0.05 vs. all other groupsb P < 0.01 vs. all other groups
P < 0.05 vs. normal and normal + 0KY046 groups
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Table 2. Renal hemodynamics in hyperglycemic and euglycemic diabetic rats
Blood RBF GFR
Body wt MAP glucose
Group g mm Hg mgldl mi/mm
SNGFR
ni/mm
Normal (5) 240 4 124 3 146 10 6.33 0.13 1.96 0.07
Hyperglycemic diabetic (5) 242 22 121 2 389 3l 7.03 0.l8 2.42 o.lOa
Euglycemic diabetic-18 hr (5) 275 8 113 2 106 10b 6.41 0.11 2.36 0.04
Euglycemic diabetic 7—10 days (6) 278 3b 122 2 109 9b 6.08 0,12b 2.22 0.03
31.9 0.6
48.9 2.7a
45.3 2.0
33.3 12b
P < 0.05 vs. normalb P < 0.05 vs. hyperglycemic diabetic
Table 3. Absolute changes due to thromboxane agonist infusion
MAP RBF GFR
Group mm Hg mi/mm
SNGFR
ni/mm
Normal (5) +1 2 —1.21 0.15 —0.38 0.03
Hyperglycemic diabetic (5) —1 3 —0.69 0.18a —0.26 0.04
Euglycemic diabetic-24 hrs (5) 0 1 —1.23 006b —045 0,03b
—7.7 1.3
—6.9 1.7
—10.4 1.0
a P < 0.05 vs. normalbP < 0.05 vs. hyperglycemic diabetic
shown in Table 4. There was a small but statistically significant
rise in all three measurements, ranging from 9 to 13%. We
previously found that the same dose of SK&F 96148 had little or
no renal hemodynamic response in normal rats, but a much
larger response (30 to 35%) was found in rats with increased
endogenous thromboxane production due to hypercholesterol-
emia [221.
Discussion
Increased renal blood flow and glomerular filtration rate are
consistently seen in early diabetes mellitus in humans and
experimental animals and are postulated to be major factors in
the pathogenesis of renal functional impairment in diabetes
mellitus [1]. The renal glomerulus produces both vasodilator
and vasoconstrictor eicosanoids which are made in increased
amounts in diabetes [9—131. Since diabetic glomeruli produce
increased amounts of the vasoconstrjctor eicosanoid thrombox-
ane A2 [91 and urinary thromboxane excretion is elevated early
in the course of diabetes in animals and patients [9, 14—17],
there may be abnormalities in renal responsiveness to throm-
boxane in the diabetic kidney. These observations led us to
hypothesize that in early diabetes, responsiveness to thrombox-
ane in the renal microcirculation may be decreased due to
reduced numbers of thromboxane receptors. Since diabetes is a
systemic disorder we reasoned that changes in thromboxane
receptors in renal glomeruli may reflect a more generalized
abnormality in thromboxane receptors in the kidneys and at
other vascular sites. Glomerular thromboxane receptors were
measured in control and 7 to 10 day diabetic rats using the
thromboxane antagonist, [3H]-SQ29548. Scatchard analysis of
equilibrium binding demonstrated one class of high affinity
thromboxane receptor sites which was virtually identical in
affinity in diabetic compared to control rats. However, there
was a 44% reduction in the number of thromboxane receptors in
untreated diabetic rats (P < 0.01).
To determine whether the apparent failure of the kidney to
respond to elevated levels of thromboxane was due to the
reduction in receptor number we examined the renal hernody-
namic response to an infusion of a stable thromboxane agonist,
U46619, The dose of U466l9 used decreased RBF, GFR and
SNGFR by approximately 20% in normal rats without affecting
blood pressure. In hyperglycemic diabetic rats the fall in RBF,
GFR and SNGFR was about 50% less than in the normal
controls. This blunted response to the thromboxane agonist was
apparent in absolute decrease as well as in percent decreases in
RBF and GFR. The data clearly demonstrate, therefore, that
renal thromboxane responsiveness is reduced in hyperglycemic
diabetic rats, which is consistent with the view that the de-
crease in thromboxane receptor number is responsible for the
failure to respond to exogenous thromboxane. However, it is
also possible that receptor occupancy by endogenous TxA2
may have been increased, and this was the reason for the
blunted response to infusion of U46619. This possibility cannot
be ruled out by the present observations. However, the fact that
infusion of the TxA2 receptor antagonist SK & F 96148 caused
only a modest rise in GFR and RBF (9 to 13%; Table 4) suggests
there was not increased occupancy of receptors by endogenous
TxA2. In a previous study in which endogenous thromboxane
was also increased due to hypercholesterolemia [221, infusion of
SK & F 96148 caused a 30 to 35% rise in RBF, GFR and
SNGFR,
Additional evidence linking the above abnormalities in hy-
perfiltration, thromboxane receptors and thromboxane respon-
siveness in the renal microcirculatjon comes from the experi-
ments in which insulin normalized blood glucose. When insulin
was administered in doses sufficient to normalize blood glucose
concentration for 7 to 10 days, renal hemodynainics, thrombox-
ane receptors and renal responsiveness to thromboxane agonist
returned to control values, In contrast, when blood glucose was
normalized for only 18 hours before study, GFR and SNGFR
were still significantly above normal control values, although
the response to U466l9 infusion was indistinguishable from that
in normal rats. Return of vascular responsiveness to thrombox-
ane that accompanies glycemic control appears to precede
complete normalization of renal hemodynamics implying that
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Fig. 3. Renal hemodynamic response to intra-aortic infusion of throm-
boxane agonist. The hyperglycemic animals were treated intermittently
with low dose NPH insulin. The euglycemic diabetic rats received
Ultralente insulin 18 hours prior to study.
factors other than a thromboxane receptor deficit also contrib-
ute to the complex disorder of diabetic hyperfiltration. Al-
though the evidence from these studies shows a strong relation-
ship between the thromboxane receptor deficit and
hyperfiltration in early diabetes, due to the complex nature of
the control of GFR it is not possible to fully assess the relative
role of the thromboxane receptor deficit compared with other
hormone abnormalities for the pathogenesis of hyperfiltration.
There are no previous studies examining the effects of
thromboxane agonist infusion on the number of renal, glomer-
ular or vascular thromboxane receptor sites in the kidney.
Thromboxane receptors have been most extensively studied in
platelet membranes. In platelet membranes, there is one report
that receptors may undergo homologous down regulation in
vitro [281. Platelet and vascular tissue are now known to have
distinct subtypes of thromboxane receptors [291, raising the
possibility that factors that regulate one group of receptor sites
may not regulate the other. In our study chronic inhibition of
thromboxane production with 0KY046 did not significantly
change the thromboxane binding in glomeruli from normal or
diabetic rats. In a small group of experiments (N = 4), the acute
infusion of a stable thromboxane agonist, U46619, did not cause
thromboxane receptor downregulation. Although other recep-
tor sites for vasoactive peptides such as angiotensin II [301 and
endothelin-1 [31] down regulate in response to acute agonist
infusion, it is possible that glomerular thromboxane receptor
sites require a longer time for down regulation. However, when
these data are considered with the chronic data on thromboxane
synthetase inhibition, it was not possible to demonstrate ho-
mologous down regulation of glomerular thromboxane receptor
sites under the conditions of our experiments.
The deficit in glomerular thromboxane receptors in diabetic
rats is similar to the defect which occurs in angiotensin II
receptors. For both angiotensin II and thromboxane the affinity
of specific receptor sites is preserved, but the number of sites is
significantly reduced in hyperfiltrating diabetics [5, 6]. Recent
evidence suggests that increases in protein kinase C induced by
hyperglycemia may down regulate glomerular receptor sites for
several vasoactive hormones and autacoids. Lee et a! [32, 33]
and Craven and de Rubertis [34] have demonstrated that
elevated glucose concentrations lead to an increase in protein
kinase C activity, an enzyme now known to be involved in the
regulation of cell surface receptors. In studies of endothelin
receptors Cozza et al [35, 36] demonstrated that protein kinase
C stimulation with the diacylglycerol analog phorbol 12-myri-
sate 13-acetate (PMA) decreased the number of endothelin
receptors in C-6 and adrenal glomerulosa cells, an effect which
could be blocked by the protein kinase C inhibitor, H-7. Similar
data were obtained in studies of the effects of phorbol esters on
angiotensin II and arginine vasopressin receptors in cultured
vascular smooth muscle cells [37, 38]. These data suggest that
there is a generalized mechanism for the decrements in a variety
of cell surface receptors in diabetes: elevated glucose stimulates
protein kinase C which in turn reduces the number of cell
surface receptors. In addition, other data suggest that PMA
may alter the expression of hormone action through mecha-
nisms independent of receptor number [39].
The mechanism of increased prostaglandin production ap-
pears to be directly related to hyperglycemia. Williams, Tsai
and Schrier [38] and Tesfamarian et al [40) demonstrated that
raising glucose concentration increased thromboxane produc-
tion in smooth muscle cells in cultures [39] and from isolated
rabbit aorta [40]. Urinary TxB2 excretion is elevated in poorly
controlled diabetes, but is normalized by insulin treatment [16].
Thus, both the increase in thromboxane production and the
decrease in thromboxane receptor number can be attributed to
events initiated by hyperglycemia. The relationship between
glomerular thromboxane production (and/or urinary excretion
of thromboxane) and GFR may be complex, and vary with the
duration of diabetes. The current studies examined this rela-
tionship only during the first week of diabetes at a time when
hyperfiltration is apparent.
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Period I Period 2 Period I Period 2 Period 1 Period 2
Hyperglycemic Diabetic (4) 121±3 121 3 7.57 0.22 8.30 0.I7 2.49±0.07 2.79 O.OT 47.8 0.1 54.3 O.4
Period I is the control period; period 2 is the intra-aortic infusion of SK & F 96148.
a P < 0.02 by Student's paired t-test.
In conclusion, this study demonstrates that there are reduced
numbers of thromboxane receptor sites and reduced renal
responsiveness to thromboxane in diabetic rats early in the
course of diabetes. Both the receptor deficit and reduced
vascular responses are restored to normal when hyperglycemia
is corrected with insulin treatment, The abnormality in throm-
boxane receptors is not likely to be due to homologous down
regulation of glomerular thromboxane receptor sites by in-
creased local levels of thromboxane, since inhibition of throm-
boxane production did not alter thromboxane binding proper-
ties. Therefore, increased renal thromboxane production in
diabetes can not effectively limit GFR because of reduced
receptor binding.
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